[go: up one dir, main page]

PL2393485T3 - Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowir - Google Patents

Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowir

Info

Publication number
PL2393485T3
PL2393485T3 PL10703766T PL10703766T PL2393485T3 PL 2393485 T3 PL2393485 T3 PL 2393485T3 PL 10703766 T PL10703766 T PL 10703766T PL 10703766 T PL10703766 T PL 10703766T PL 2393485 T3 PL2393485 T3 PL 2393485T3
Authority
PL
Poland
Prior art keywords
cobicistat
elvitegravir
emtricitabine
tenofovir
bilayer tablets
Prior art date
Application number
PL10703766T
Other languages
English (en)
Inventor
Reza Oliyai
Mark M Menning
Joanna M Koziara
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2393485(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PL2393485T3 publication Critical patent/PL2393485T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL10703766T 2009-02-06 2010-02-04 Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowir PL2393485T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15065509P 2009-02-06 2009-02-06
US15065209P 2009-02-06 2009-02-06
PCT/US2010/023226 WO2010091197A2 (en) 2009-02-06 2010-02-04 Tablets for combination therapy
EP10703766.5A EP2393485B1 (en) 2009-02-06 2010-02-04 Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir

Publications (1)

Publication Number Publication Date
PL2393485T3 true PL2393485T3 (pl) 2015-12-31

Family

ID=41722740

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10703766T PL2393485T3 (pl) 2009-02-06 2010-02-04 Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowir

Country Status (30)

Country Link
US (2) US20100285122A1 (pl)
EP (1) EP2393485B1 (pl)
JP (2) JP5611242B2 (pl)
KR (2) KR101645759B1 (pl)
CN (1) CN102307573B (pl)
AP (1) AP3250A (pl)
AR (1) AR075369A1 (pl)
AU (1) AU2010210598B2 (pl)
BR (1) BRPI1008664A2 (pl)
CA (1) CA2750521A1 (pl)
CL (1) CL2011001885A1 (pl)
CY (1) CY1116852T1 (pl)
DK (1) DK2393485T3 (pl)
EA (2) EA030123B1 (pl)
EC (1) ECSP11011307A (pl)
ES (1) ES2548886T3 (pl)
HR (1) HRP20151009T1 (pl)
HU (1) HUE025822T2 (pl)
IL (1) IL214227A (pl)
MX (1) MX2011008289A (pl)
NZ (1) NZ594214A (pl)
PE (1) PE20110994A1 (pl)
PL (1) PL2393485T3 (pl)
PT (1) PT2393485E (pl)
SG (3) SG173544A1 (pl)
SI (1) SI2393485T1 (pl)
SM (1) SMT201500266B (pl)
TW (1) TWI444367B (pl)
UY (1) UY32424A (pl)
WO (1) WO2010091197A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2049506T2 (sl) 2006-07-07 2024-07-31 Gilead Sciences, Inc. Modulatorji farmakokinetičnih lastnosti terapevtikov
ES2779826T3 (es) * 2007-02-23 2020-08-20 Gilead Sciences Inc Moduladores de propiedades farmacocinéticas de agentes terapéuticos
MX342377B (es) 2008-05-02 2016-09-27 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
EA025852B1 (ru) 2010-11-19 2017-02-28 Джилид Сайэнс, Инк. ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ РИЛПИВИРИН HCl И ТЕНОФОВИРА ДИЗОПРОКСИЛФУМАРАТ
PL2646005T3 (pl) * 2010-11-29 2019-12-31 Formac Pharmaceuticals N.V. Sprasowane formulacje uporządkowanych, mezoporowatych krzemionek
US20140142070A1 (en) 2011-07-07 2014-05-22 Janssen R&D Ireland Darunavir combination formulations
PE20141328A1 (es) 2011-08-16 2014-10-04 Gilead Sciences Inc Tenofovir alafenamida hemifumarato
US20150105350A1 (en) * 2012-02-03 2015-04-16 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
AU2012327170A1 (en) * 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
WO2013130766A1 (en) * 2012-03-01 2013-09-06 Gilead Sciences, Inc. Spray dried formulations
CN103830192A (zh) * 2012-11-27 2014-06-04 安徽贝克生物制药有限公司 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法
SI3067358T1 (sl) 2012-12-21 2019-12-31 Gilead Sciences, Inc. Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
MX2017016806A (es) 2015-06-30 2018-05-07 Gilead Sciences Inc Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina.
CN108348473B (zh) 2015-11-09 2021-06-18 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
EP3411378B1 (en) 2016-02-02 2020-03-25 Sandoz AG Crystalline forms of tenofovir alafenamide monofumarate
EP4196096A1 (en) * 2020-08-13 2023-06-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant high-strength formulation containing posaconazole

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
DE10153078A1 (de) * 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
JP3567162B1 (ja) * 2002-11-20 2004-09-22 日本たばこ産業株式会社 4−オキソキノリン化合物及びそのhivインテグラーゼ阻害剤としての利用
BRPI0306214B1 (pt) * 2002-11-20 2017-08-08 Japan Tobacco Inc. 4-oxoquinoline compound and use of this as a hiv integrase inhibitor
CN100375742C (zh) * 2002-11-20 2008-03-19 日本烟草产业株式会社 4-氧代喹啉化合物及其用途
AU2004206821C1 (en) 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CA2633603C (en) * 2005-12-14 2016-09-13 Cipla Limited Pharmaceutical combination
SI2049506T2 (sl) 2006-07-07 2024-07-31 Gilead Sciences, Inc. Modulatorji farmakokinetičnih lastnosti terapevtikov
ES2779826T3 (es) * 2007-02-23 2020-08-20 Gilead Sciences Inc Moduladores de propiedades farmacocinéticas de agentes terapéuticos

Also Published As

Publication number Publication date
EA201190125A1 (ru) 2012-01-30
CN102307573A (zh) 2012-01-04
US20100285122A1 (en) 2010-11-11
TWI444367B (zh) 2014-07-11
SG10201706215UA (en) 2017-08-30
US20150150810A1 (en) 2015-06-04
PT2393485E (pt) 2015-10-23
TW201040142A (en) 2010-11-16
KR20110122729A (ko) 2011-11-10
EA201491658A1 (ru) 2015-05-29
JP2014221845A (ja) 2014-11-27
JP5911927B2 (ja) 2016-04-27
WO2010091197A2 (en) 2010-08-12
AR075369A1 (es) 2011-03-30
EP2393485A2 (en) 2011-12-14
ES2548886T3 (es) 2015-10-21
CY1116852T1 (el) 2017-04-05
CA2750521A1 (en) 2010-08-12
AP3250A (en) 2015-05-31
DK2393485T3 (en) 2015-10-26
CL2011001885A1 (es) 2012-05-25
PE20110994A1 (es) 2012-01-24
EP2393485B1 (en) 2015-07-29
SI2393485T1 (sl) 2015-10-30
AU2010210598A1 (en) 2011-08-25
WO2010091197A3 (en) 2011-06-03
JP5611242B2 (ja) 2014-10-22
JP2012517432A (ja) 2012-08-02
SG173544A1 (en) 2011-09-29
ECSP11011307A (es) 2011-10-31
SG2014007744A (en) 2014-05-29
KR20160093100A (ko) 2016-08-05
CN102307573B (zh) 2013-09-11
MX2011008289A (es) 2011-09-15
AU2010210598B2 (en) 2015-03-05
UY32424A (es) 2010-09-30
EA030123B1 (ru) 2018-06-29
HRP20151009T1 (hr) 2015-10-23
BRPI1008664A2 (pt) 2016-03-08
IL214227A (en) 2017-01-31
IL214227A0 (en) 2011-09-27
EA021313B1 (ru) 2015-05-29
AP2011005857A0 (en) 2011-10-31
SMT201500266B (it) 2016-01-08
KR101645759B1 (ko) 2016-08-04
KR101738325B1 (ko) 2017-05-19
HK1164737A1 (en) 2012-09-28
NZ594214A (en) 2013-05-31
HUE025822T2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
SI2393485T1 (sl) Dvoslojne tablete, ki vsebujejo elvitegravir, cobicistat, emtricitabin in tenofovir
HUS2000009I1 (hu) Kétrétegû tabletta készítmények
SI2464342T1 (sl) Farmacevtske formulacije proti zlorabi zdravil
IL220509A (en) Compressed pyridinylpyrolidone, a pharmaceutical preparation and combination
ZA201201605B (en) Highly concentrated pharmaceutical formulations comprising anti-cd20 antibody
IL217224B (en) Pyrazolopyrimides, pharmaceutical preparations containing them and their use
IL217762A0 (en) Pharmaceutical formulation
EP2481739A4 (en) DIHYDROPTERIDINONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL USE
IL279626A (en) Increasing the bioavailability of a drug in treatment with naltrexone
PL2655375T3 (pl) Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie
IL214402A0 (en) Transdermal pharmaceutical preparations
ZA201200366B (en) 3-cyanoquinoline tablet formulations and uses thereof
ZA200903858B (en) Pharmaceutical dosage form
GB0815972D0 (en) Pharmaceutical preparation
IL219617A0 (en) Pharmaceutical solid dosage form
PL2309983T3 (pl) Farmaceutyczna postać podawania zawierająca tetrahydrobiopterynę
IL229206A0 (en) Preparation and tablet containing raltagravir
PL2651390T3 (pl) Orodyspersyjna tabletka farmaceutyczna na bazie zolpidemu
GB0922537D0 (en) Pharmaceutical preparation
GB201115173D0 (en) Pharmaceutical preparation
GB0906003D0 (en) Oral drug formulation
HU1000106V0 (en) Dispenser for drugs in solid form
HK1175118A (en) Pharmaceutical solid dosage form
GB0914989D0 (en) Drug release formulations